81 research outputs found
Recommended from our members
Biodegradable, flexible silicon nanomembrane-based NO x gas sensor system with record-high performance for transient environmental monitors and medical implants
Abstract: A novel transient electronics technology that is capable of completely dissolving or decomposing in certain conditions after a period of operation offers unprecedented opportunities for medical implants, environmental sensors, and other applications. Here, we describe a biodegradable, flexible silicon-based electronic system that detects NO species with a record-breaking sensitivity of 136 Rs (5 ppm, NO2) and 100-fold selectivity for NO species over other substances with a fast response (~30 s) and recovery (~60 s). The exceptional features primarily depend on not only materials, dimensions, and design layouts but also temperatures and electrical operations. Large-scale sensor arrays in a mechanically pliable configuration exhibit negligible deterioration in performance under various modes of applied loads, consistent with mechanics modeling. In vitro evaluations demonstrate the capability and stability of integrated NOx devices in severe wet environments for biomedical applications
Bioresorbable silicon electronics for transient spatiotemporal mapping of electrical activity from the cerebral cortex.
Bioresorbable silicon electronics technology offers unprecedented opportunities to deploy advanced implantable monitoring systems that eliminate risks, cost and discomfort associated with surgical extraction. Applications include postoperative monitoring and transient physiologic recording after percutaneous or minimally invasive placement of vascular, cardiac, orthopaedic, neural or other devices. We present an embodiment of these materials in both passive and actively addressed arrays of bioresorbable silicon electrodes with multiplexing capabilities, which record in vivo electrophysiological signals from the cortical surface and the subgaleal space. The devices detect normal physiologic and epileptiform activity, both in acute and chronic recordings. Comparative studies show sensor performance comparable to standard clinical systems and reduced tissue reactivity relative to conventional clinical electrocorticography (ECoG) electrodes. This technology offers general applicability in neural interfaces, with additional potential utility in treatment of disorders where transient monitoring and modulation of physiologic function, implant integrity and tissue recovery or regeneration are required
Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study.
BACKGROUND: CheckMate 040 assessed the efficacy and safety of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety profile of nivolumab is needed to support the management of treatment-related adverse events (TRAEs). This analysis assessed the safety of nivolumab monotherapy in the phase I/II, open-label CheckMate 040 study.
MATERIALS AND METHODS: Select TRAEs (sTRAEs; TRAEs with potential immunologic etiology requiring more frequent monitoring) occurring between first dose and 30 days after last dose were analyzed in patients in the dose-escalation and -expansion phases. Time to onset (TTO), time to resolution (TTR), and recurrence of sTRAEs were assessed, and the outcome of treatment with immune-modulating medication (IMM) was evaluated.
RESULTS: The analysis included 262 patients. The most common sTRAE was skin (35.5%), followed by gastrointestinal (14.5%) and hepatic (14.1%) events; the majority were grade 1/2, with 10.7% of patients experiencing grade 3/4 events. One patient had grade 5 pneumonitis. Median (range) TTO ranged from 3.6 (0.1-59.9) weeks for skin sTRAEs to 47.6 (47.1-48.0) weeks for renal sTRAEs. Overall, 68% of sTRAEs resolved, with median (range) TTR ranging from 3.7 (0.1-123.3+) weeks for gastrointestinal sTRAEs to 28.4 (0.1-79.1) weeks for endocrine sTRAEs. Most gastrointestinal and all hepatic events resolved with treatment in accordance with established toxicity management algorithms. In 57 patients (40%), sTRAEs were managed with IMM. Reoccurrence of sTRAEs was uncommon following rechallenge with nivolumab.
CONCLUSION: Nivolumab demonstrated a manageable safety profile in this analysis of patients with advanced HCC. A majority of sTRAEs resolved with treatment.
IMPLICATIONS FOR PRACTICE: Nivolumab is a viable treatment option for patients with previously treated advanced hepatocellular carcinoma as it has demonstrated durable tumor responses and promising survival. Nivolumab has a manageable safety profile. The most common select treatment-related adverse events (sTRAEs) in this analysis were skin related (35%). Gastrointestinal and hepatic sTRAEs were observed in approximately 14% of patients. The majority of sTRAEs resolved (68%). Safety events are easier to manage if addressed early. Patient education on signs and symptoms to watch out for and the importance of early reporting and consultation should be emphasized
Pre‐symptomatic transmission of novel coronavirus in community settings
We used contact tracing to document how COVID‐19 was transmitted across 5 generations involving 10 cases, starting with an individual who became ill on January 27. We calculated the incubation period of the cases as the interval between infection and development of symptoms. The median incubation period was 6.0 days (interquartile range, 3.5‐9.5 days). The last two generations were infected in public places, 3 and 4 days prior to the onset of illness in their infectors. Both had certain underlying conditions and comorbidity. Further identification of how individuals transmit prior to being symptomatic will have important consequences.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/163478/2/irv12773.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/163478/1/irv12773_am.pd
Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment-Related Adverse Events From the CheckMate 040 Study
Background. CheckMate 040 assessed the efficacy and safety
of nivolumab in patients with advanced hepatocellular carcinoma (HCC). Understanding the safety profile of nivolumab is
needed to support the management of treatment-related
adverse events (TRAEs). This analysis assessed the safety
of nivolumab monotherapy in the phase I/II, open-label
CheckMate 040 study.
Materials and Methods. Select TRAEs (sTRAEs; TRAEs with
potential immunologic etiology requiring more frequent
monitoring) occurring between first dose and 30 days after
last dose were analyzed in patients in the dose-escalation
and -expansion phases. Time to onset (TTO), time to resolution (TTR), and recurrence of sTRAEs were assessed, and
the outcome of treatment with immune-modulating medication (IMM) was evaluated.
Results. The analysis included 262 patients. The most common sTRAE was skin (35.5%), followed by gastrointestinal
(14.5%) and hepatic (14.1%) events; the majority were grade
1/2, with 10.7% of patients experiencing grade 3/4 events.
One patient had grade 5 pneumonitis. Median (range) TTO
ranged from 3.6 (0.1–59.9) weeks for skin sTRAEs to 47.6
(47.1–48.0) weeks for renal sTRAEs. Overall, 68% of sTRAEs
resolved, with median (range) TTR ranging from 3.7
(0.1–123.3+) weeks for gastrointestinal sTRAEs to 28.4
(0.1–79.1) weeks for endocrine sTRAEs. Most gastrointestinal
and all hepatic events resolved with treatment in accordance
with established toxicity management algorithms. In
57 patients (40%), sTRAEs were managed with IMM.
Reoccurrence of sTRAEs was uncommon following rechallenge
with nivolumab.
Conclusion. Nivolumab demonstrated a manageable safety
profile in this analysis of patients with advanced HCC. A
majority of sTRAEs resolved with treatment
Insight-HXMT observations of Swift J0243.6+6124 during its 2017-2018 outburst
The recently discovered neutron star transient Swift J0243.6+6124 has been
monitored by {\it the Hard X-ray Modulation Telescope} ({\it Insight-\rm HXMT).
Based on the obtained data, we investigate the broadband spectrum of the source
throughout the outburst. We estimate the broadband flux of the source and
search for possible cyclotron line in the broadband spectrum. No evidence of
line-like features is, however, found up to . In the absence of
any cyclotron line in its energy spectrum, we estimate the magnetic field of
the source based on the observed spin evolution of the neutron star by applying
two accretion torque models. In both cases, we get consistent results with
, and peak luminosity of which makes the source the first Galactic ultraluminous
X-ray source hosting a neutron star.Comment: publishe
Overview to the Hard X-ray Modulation Telescope (Insight-HXMT) Satellite
As China's first X-ray astronomical satellite, the Hard X-ray Modulation
Telescope (HXMT), which was dubbed as Insight-HXMT after the launch on June 15,
2017, is a wide-band (1-250 keV) slat-collimator-based X-ray astronomy
satellite with the capability of all-sky monitoring in 0.2-3 MeV. It was
designed to perform pointing, scanning and gamma-ray burst (GRB) observations
and, based on the Direct Demodulation Method (DDM), the image of the scanned
sky region can be reconstructed. Here we give an overview of the mission and
its progresses, including payload, core sciences, ground calibration/facility,
ground segment, data archive, software, in-orbit performance, calibration,
background model, observations and some preliminary results.Comment: 29 pages, 40 figures, 6 tables, to appear in Sci. China-Phys. Mech.
Astron. arXiv admin note: text overlap with arXiv:1910.0443
- …